Barron's: Stock buy, dividend hike could boost Pfizer

A big stock buyback or an increased dividend could lift Pfizer shares to $25 over the next year, and the retirement of former CEO Jeff Kindler also gives Pfizer an opportunity to shed assets, Barron's said. Report

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.